Table 1

Relationships between p16 or PD-L1 expression and patient characteristics

CharacteristicsNo of patients (%)p16P valueTC-PD-L1P valueIC-PD-L1P value
Negative (%)Positive (%)<5% (%)≥5% (%)<5% (%)≥5% (%)
13778 (56.9)59 (43.1)56 (40.9)81 (59.1)54 (39.4)83 (60.6)
Age (years)0.0830.7280.728
 <6362 (45.3)303224382240
 ≥6375 (54.7)482732433243
Sex0.50.039*0.358
 Male113 (82.5)664751624766
 Female24 (17.5)1212519717
Smoking status0.019*0.201*0.016
 No33 (24.1)14191023825
 Yes98 (71.5)584042564157
 Unknown6 (4.4)604251
Alcohol status0.001*0.07*0.007
 No39 (28.5)152412271128
 Yes90 (65.7)553538523654
 Unknown8 (5.8)806271
Differentiation0.007*0.008**0.008
 Well or moderately116 (84.7)724453635264
 Poorly21 (15.3)615318219
cT stage0.60510.861
 T1 or T278 (56.9)463232463048
 T3 or T459 (43.1)322724352435
cN stage0.001*0.038*0.861
 N0 or N161 (44.5)441731302536
 N2 or N376 (55.5)344225512947
cStage<0.001*0.012*0.532
 I or II31 (22.6)27419121417
 III or IV106 (77.4)515537694066
Definitive treatment0.2160.032*0.477
 Surgery53 (38.7)341928252330
 CRT or RT84 (61.3)444028563153
  • CRT, chemoradiotherapy; IC-PD-L1, programmed death ligand 1 on immune cells; RT, radiotherapy; TC-PD-L1, programmed death ligand 1 on tumour cells.